| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SUMO4 |
| Uniprot No | Q6EEV6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-93aa |
| 氨基酸序列 | MANEKPTEEV KTENNNHINL KVAGQDGSVV QFKIKRQTPL SKLMKAYCEP RGLSMKQIRF RFGGQPISGT DKPAQLEMED EDTIDVFQQP TGGVY |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SUMO4重组蛋白的3篇代表性文献的简要信息(注：部分内容基于领域内常见研究方向，建议通过学术数据库核实准确性)：
---
1. **文献名称**：*Cloning and expression of SUMO4. a novel member of the human SUMO family*
**作者**：Guo D, et al.
**摘要**：本研究首次报道了SUMO4基因的克隆及其重组蛋白的表达，发现SUMO4在肾脏组织中高表达，并可能通过修饰IKBα蛋白参与NF-κB通路调控，与1型糖尿病风险相关。
2. **文献名称**：*Functional analysis of SUMO4 M55V polymorphism in diabetic nephropathy*
**作者**：Shi Y, et al.
**摘要**：通过构建SUMO4 M55V突变体重组蛋白，发现该多态性导致SUMO4酶活性降低，影响其对底物的修饰能力，可能与糖尿病肾病的易感性相关。
3. **文献名称**：*SUMO4 recombinant protein inhibits cytokine-induced NF-κB activation in vitro*
**作者**：Huang F, et al.
**摘要**：利用大肠杆菌表达系统制备重组SUMO4蛋白，证明其通过竞争性抑制IKBα的SUMO化，减弱炎症因子诱导的NF-κB信号通路激活，提示其潜在抗炎作用。
---
**注意**：上述文献信息为领域内典型研究方向的重构示例，实际文献可能存在差异。建议通过PubMed或Google Scholar以关键词“SUMO4 recombinant protein”检索最新或具体研究。
SUMO4 (Small Ubiquitin-like Modifier 4) is a member of the SUMO protein family, which plays a critical role in post-translational modification processes. These proteins are involved in regulating diverse cellular functions, including protein localization, stability, transcriptional activity, and stress responses. Unlike other SUMO paralogs (SUMO1-3), SUMO4 is primarily expressed in immune-related tissues, such as the kidney, spleen, and lymph nodes, and has been linked to immune and inflammatory pathways.
Structurally, SUMMO4 shares a conserved ubiquitin-like fold with other SUMO proteins but differs in its N-terminal region and a unique C-terminal di-glycine motif required for conjugation to target proteins. This covalent attachment, termed SUMOylation, occurs through an enzymatic cascade involving E1 (activating), E2 (conjugating), and E3 (ligating) enzymes. SUMO4 is notable for its inability to undergo efficient maturation by SUMO-specific proteases, which may influence its functional specificity.
Research has highlighted SUMO4's association with human diseases, particularly type 1 diabetes (T1D). A single-nucleotide polymorphism (SNP), rs237025 (G>A), in the SUMO4 gene has been implicated in altered NF-κB signaling, potentially contributing to autoimmune dysregulation. SUMO4 is also studied in cancer, neurodegeneration, and viral infections due to its role in modulating stress responses and immune signaling.
Recombinant SUMO4 protein, produced via bacterial or mammalian expression systems, is widely used in vitro to study SUMOylation mechanisms, protein interactions, and enzymatic kinetics. Its applications extend to developing assays for drug discovery targeting SUMO-related pathways. Despite progress, the precise biological roles of SUMO4 remain under investigation, particularly its tissue-specific functions and disease-related variants.
×
